Cancer Genetics

Cancer Genetics, Inc. (CGI) is an emerging leader in DNA-based cancer diagnostics and services some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also provide a comprehensive range of non-proprietary oncology-focused tests and laboratory services.
CGI’s cutting-edge proprietary tests and state- of-the-art reference laboratory provide critical genomic information to healthcare professionals as well as biopharma and biotech. Our state of the art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State.
The company was founded in 1999 by world-renowned cytogeneticist Dr. R.S.K. Chaganti; and has since built on a foundation of world-class scientific knowledge and IP in solid and blood-borne cancers, while also establishing strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic and the National Cancer Institute.

Company growth
Type
Public
HQ
Rutherford, US
Founded
1999
Size (employees)
223 (est)+61%
Cancer Genetics was founded in 1999 and is headquartered in Rutherford, US

Key People at Cancer Genetics

Panna Sharma

Panna Sharma

President & CEO
Edward Sitar

Edward Sitar

CFO & Treasurer
Elizabeth Czerepak

Elizabeth Czerepak

Chief Financial Officer and Principal Accounting Officer

Cancer Genetics Office Locations

Cancer Genetics has offices in Rutherford, Shanghai, Los Angeles, Morrisville
Rutherford, US
Shanghai, CN
Los Angeles, US
Morrisville, US

Cancer Genetics Metrics

Cancer Genetics Summary

Market capitalization

$47.2 M

Closing share price

$2.45
Cancer Genetics's current market capitalization is $47.2 M.

Cancer Genetics Financials

Cancer Genetics's revenue is $18 M in FY, 2015 which is 76.87% increase from the previous period.
FY, 2015FY, 2014FY, 2013

Revenue

$18 M$10.2 M$6.61 M

Revenue growth, %

76.9%54.3%

Gross profit

$3.94 M$1.75 M$1.69 M

Operating income

$-20.7 M$-18.3 M$-8.45 M

Operating expense total

$25.3 M$21 M$10.1 M

Net Income

$-20.2 M$-16.6 M$-12.4 M

Operating cash flow

$-6.1 M$-23.9 M$48.6 M

Cancer Genetics Market Value History

Cancer Genetics Online Presence

Cancer Genetics News

Cancer Genetics Company Life

You may also be interested in